FTC takes closer look at Cencora-Covetrus animal health merger, Bloomberg News reports
Reuters reports the FTC is reviewing a proposed $3.5 billion deal combining Cencora’s MWI Animal Health with Covetrus, after Bloomberg said the agency issued information requests to Covetrus customers and rivals. The requests cover effects on veterinary product availability and practice-management software. Cencora said it would sell MWI Animal Health to Covetrus in February.
How this was made
The 30-second read
Why it matters
The FTC’s information demands suggest active antitrust review of the proposed $3.5B combination, with potential implications for deal timing, required remedies, and near-term trading in deal-related positions.
Market read
Regulatory review risk increases for the Cencora-Covetrus veterinary products deal after the FTC issues information demands, which can move deal spreads and clearance expectations.
What to watch
The article does not detail whether the FTC is focused on specific product categories or software workflows, which could determine whether remedies are likely or the review is routine.
Background
Cencora said in February it would sell MWI Animal Health to Covetrus as it refocuses on drug distribution and divests non-core businesses.
Market effects
Could raise perceived antitrust scrutiny for veterinary product and practice-management software consolidation, affecting deal appetite in adjacent healthcare services.
Primarily US regulatory process, with potential spillover to global veterinary distribution M&A expectations.
Limited direct global impact unless the FTC’s approach influences other jurisdictions’ review standards.
Counterpoint
Information demands do not imply the FTC will block the deal; many transactions proceed after document production and negotiations.
Key entities
- companyCencora
Seller of MWI Animal Health in the proposed $3.5B acquisition by Covetrus.
- companyCovetrus
Buyer in the proposed combination; subject of FTC information demands to customers and rivals.
- companyMWI Animal Health
Veterinary products supplier being combined with Covetrus via Cencora’s planned divestiture.
- regulatorFederal Trade Commission (FTC)
Antitrust agency issuing information demands as part of its review of the proposed merger.
